stockrowHUTCHMED (China) Limited Sponsored ADR
HCM Healthcare Drug Manufacturers Specialty & Generic
HUTCHMED (China) Limited Sponsored ADR’s revenue for fiscal 2025 (year ended December 2025) was $548.5 million, down 13.0% from fiscal 2024.
Follow HCM
Alert me
HUTCHMED (China) Limited Sponsored ADR (HCM) EV/FCF
As of 5 November 2026, HUTCHMED (China) Limited Sponsored ADR (HCM) trades at a EV/FCF of 7.5×. Over the past ten years it has ranged from 0.0× (June 2016) to 82.0× (June 2018); the current reading is higher than 74% of that period.
EV/FCF, daily
Embed this chart
Annual newest first
| Period | EV/FCF | Change |
|---|---|---|
| FY2025 | 5.6× | 29.80% |
| FY2024 | 4.3× | (88.18%) |
| FY2023 | 36.4× | 4,381.75% |
| FY2022 | 0.8× | (15.38%) |
| FY2021 | 1.0× | (63.48%) |
| FY2020 | 2.6× | 120.17% |
| FY2019 | 1.2× | (74.65%) |
| FY2018 | 4.7× | (94.26%) |
| FY2017 | 82.0× | 2,654.58% |
| FY2016 | 3.0× | — |
Quarterly newest first
| Period | EV/FCF | Change |
|---|---|---|
| Jun 2023 | −21.8× | — |
| Dec 2022 | −19.1× | — |
| Jun 2022 | −15.0× | — |
| Jun 2021 | −12.7× | — |
| 10 more quarters | Free account |
Against its own ten years
EV/FCF against peers
| Company | EV/FCF |
|---|---|
| ALVO Alvotech compare | −11.9× |
| RGC Regencell Bioscience Holdings Limited compare | 0.9× |
| BCRX BioCryst Pharmaceuticals, Inc. compare | 6.6× |
| HCM HUTCHMED (China) Limited Sponsored ADR | 7.5× |
| ANIP ANI Pharmaceuticals, Inc. compare | 8.2× |
| TRLV Trulieve Cannabis Corp. compare | 12.0× |
| PBH Prestige Consumer Healthcare Inc. compare | 19.2× |
| PRGO Perrigo Company plc compare | 28.6× |
| XERS Xeris Biopharma Holdings, Inc. compare | 33.9× |
What EV/FCF is
EV/Free CF shows how the value of a whole company, debt included, compares with the free cash its business produces.
((Stock Price × Shares (Basic, Weighted) (latest quarter)) + (Long Term Debt (Total) (latest quarter) + Current Part of Debt (latest quarter)) − Cash & Short Term Investments (latest quarter)) ÷ (Operating Cash Flow (TTM) + Property, Plant, Equipment Change (Net) (TTM) + Intangible Assets Change (Net) (TTM))
More on HCM
- Revenue
- Net income
- EBITDA
- Free cash flow
- Operating cash flow
- Gross margin
- Operating margin
- Net margin
- Free cash flow margin
- P/E ratio
- P/S ratio
- P/B ratio
- Price to free cash flow
- EV/EBITDA
- EV/Sales
- Return on equity
- Return on assets
- Return on invested capital
- Debt to equity
- Current ratio
- Total debt
- Shares outstanding
- Book value per share
- Revenue growth
- Piotroski F-score
- Altman Z-score
- Beneish M-score
- The full statement